drugset / Trial / NCT02535299
Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment
NaSingle-groupOpen-labelTreatment
Summary
Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.2 mg | — |
| Subject | Liraglutide | Peptide | 1.8 mg | — |
| Subject | Metformin | Small molecule | 1500 mg | — |
| Subject | Metformin | Small molecule | 2000 mg | — |
Indications
No indication recorded.